Reuters logo
BRIEF-Celgene and Nimbus Therapeutics enter long-term strategic immunology alliance to develop programs for patients with autoimmune disorders
October 3, 2017 / 11:37 AM / 2 months ago

BRIEF-Celgene and Nimbus Therapeutics enter long-term strategic immunology alliance to develop programs for patients with autoimmune disorders

Oct 3 (Reuters) - Celgene Corp:

* Nimbus therapeutics and Celgene enter long-term strategic immunology alliance to develop programs for patients with autoimmune disorders

* Celgene Corp - ‍financial terms will remain undisclosed until Celgene acquires a program​

* Celgene Corp - ‍Celgene will receive an option to acquire each program in alliance up through a clinical inflection point​

* Celgene Corp - ‍Nimbus will receive an upfront payment and potential downstream milestone payments for each program celgene chooses to acquire​

* Celgene Corp - ‍Nimbus will retain full control of research and development activities for each program prior to program’s option point​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below